Post-earnings recap
Reported
Tue, May 5, 2026
EPS actual
$-0.40
EPS est.
$-0.57
EPS surprise
+30.31%
1-day move
+6.09%
Alkermes reported a larger-than-expected loss per share, which surprised analysts. Despite the EPS miss, the stock rose by 6.09%, likely driven by investor optimism about future performance or other underlying factors not detailed in the earnings call.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.40 | $-0.04 | +30.31% |
| Revenue | — | $361M | — |
No transcript is on record, so the analysis is based solely on numerical results.
Alkermes plc is a biotechnology company focused on developing innovative medicines for people with serious mental health conditions and addiction. Operating in the health care sector, Alkermes plays a crucial role in addressing unmet medical needs through its research and development efforts.
Last quarter
In Q4 2025, Alkermes reported an EPS of $0.29, slightly missing expectations. The stock reacted negatively, dropping 7.04% the following day.
EPS beat streak
2Q
EPS beat rate
75%
Avg EPS surprise
+31.51%
Avg 1-day reaction
+1.24%
Analysts expect Alkermes to report a loss this quarter, with a consensus EPS of $-0.04 and revenue of $361 million. The market is cautious given the company's recent performance.
Bull case
If Alkermes can exceed revenue expectations and show signs of improved profitability, it could boost investor confidence and lead to a positive stock reaction.
Bear case
A continued trend of missing earnings expectations could further erode investor trust and lead to a significant decline in stock price.
Key metrics to watch
EPS
$-0.04Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.
Revenue
$361MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Alkermes report revenue above the consensus estimate of $361 million?
Exceeding revenue expectations could signal strong demand for its products and improve investor sentiment.
Q2
How will management address the recent trend of missing EPS expectations?
Investors will be looking for reassurances or strategies to improve profitability moving forward.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The consensus may underestimate the potential for Alkermes to surprise on revenue, as recent product launches could drive higher sales than anticipated.
Supporting evidence
The company's innovative pipeline may yield unexpected revenue growth.
Options pricing suggests traders are anticipating a larger move than historical averages, indicating potential for a surprise.
Key risk
If revenue exceeds $379 million, it could challenge the bearish outlook and shift sentiment positively.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it follows a history of mixed earnings results, and investor expectations are cautious.
Bull confirmed if
A revenue figure above $361 million would confirm the bull case and suggest strong market performance.
Bear confirmed if
An EPS loss greater than the consensus of $-0.04 would validate the bear case.
What the market is pricing for the move.
Implied Move
±8.59%
Historical Avg
±5.0%
The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±7.6% while ALKS has averaged ±5.0% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
56.8%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$3.8M
76,150 sh
4 insiders
Net
$3.8M
Net selling
Most Active Insiders· 8 open-market trades
$279,919.08
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
107.45%
of float
Insider
1.40%
of float
Holders
569
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
29,235,739 sh · $1.2B
17.43%
3.3%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Alkermes beats expectations, history suggests the stock could rise by about 2.97%, confirming a positive turnaround.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.
Miss
A miss could lead to a decline, with historical averages suggesting a drop of around 0.97%.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
1 buy·0 sells
Members
1
House only
Est. Notional
$15,001.00–$50,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
$860,094.00
Net selling
$372,936.74
Net selling
$2.2M
Net selling
Recent Transactions
Aug 3, 2026 · @ $50.35
44,472 sh
$2.2M
Aug 3, 2026 · @ $48.58
9,000 sh
$437,220.00
Sep 1, 2026 · @ $46.99
9,000 sh
$422,874.00
Aug 17, 2026 · @ $49.19
6,912 sh
$339,967.41
Aug 3, 2026 · @ $48.58
2,034 sh
$98,811.72
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Baker Bros. Advisors, LP
10,012,267 sh · $415.0M
5.97%
Flat
Vanguard Portfolio Management LLC
9,490,818 sh · $393.3M
5.66%
-0.2%
State Street Corporation
9,160,575 sh · $379.7M
5.46%
-3.2%
Vanguard Capital Management LLC
7,515,025 sh · $311.5M
4.48%
1.2%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net buying
Recent Transactions
Traded Jul 30, 2026 · disclosed Sep 4, 2026
$15,001.00–$50,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.